Serum CXCL13 Level is Associated with Tumor Progression and Unfavorable Prognosis in Penile Cancer

References

• Douglawi A, Masterson TA. Updates on the epidemiology and risk factors for penile cancer. Transl Androl Urol. 2017;6(5):785–790. doi:10.21037/tau.2017.05.1929184774
   PubMed Web of Science ®Google Scholar
• Barski D, Georgas E, Gerullis H, Ecke T. Metastatic penile carcinoma - an update on the current diagnosis and treatment options. Cent European J Urol. 2014;67(2):126–132. doi:10.5173/ceju.2014.02.art2
   PubMedGoogle Scholar
• Capone F, Guerriero E, Sorice A, Colonna G, Ciliberto G, Costantini S. Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays. Mediators Inflamm. 2016;2016:3064643. doi:10.1155/2016/306464328050120
   PubMed Web of Science ®Google Scholar
• Wang J, Chu Y, Li J, et al. The clinical value of carcinoembryonic antigen for tumor metastasis assessment in lung cancer. PeerJ. 2019;7(7):e7433. doi:10.7717/peerj.743331410309
   PubMedGoogle Scholar
• Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13(1):129. doi:10.1186/1476-4598-13-12924886523
   PubMed Web of Science ®Google Scholar
• Nam SE, Lim W, Jeong J, et al. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. Breast Cancer Res Treat. 2019;177(3):669–678. doi:10.1007/s10549-019-05357-y31312932
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ye DW, Yao XD, et al. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer. J Urol. 2008;180(5):2019–2023. doi:10.1016/j.juro.2008.07.04018801542
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–550. doi:10.1038/nrc138815229479
   PubMed Web of Science ®Google Scholar
• Chen X, Chen R, Jin R, Huang Z. The role of CXCL chemokine family in the development and progression of gastric cancer. Int J Clin Exp Pathol. 2020;13(3):484–492.32269686
   PubMed Web of Science ®Google Scholar
• Do HTT, Lee CH, Cho J. Chemokines and their Receptors: multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. Cancers. 2020;12(2):287. doi:10.3390/cancers12020287
   PubMed Web of Science ®Google Scholar
• Amiri KI, Richmond A. Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol. 2003;74:1–36.14510072
   PubMedGoogle Scholar
• Aldinucci D, Colombatti A. The inflammatory chemokine CXCL5 and cancer progression. Mediators Inflamm. 2014;2014:292376. doi:10.1155/2014/29237624523569
   PubMed Web of Science ®Google Scholar
• Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 2017;7(6):1543–1588. doi:10.7150/thno.1562528529637
   PubMed Web of Science ®Google Scholar
• Karin N, Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine. 2018;109:24–28. doi:10.1016/j.cyto.2018.02.01229449068
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40–47. doi:10.1016/j.ctrv.2017.11.00729207310
   PubMed Web of Science ®Google Scholar
• Kazanietz MG, Durando M, Cooke M. CXCL13 and Its Receptor CXCR5 in Cancer: inflammation, Immune Response, and Beyond. Front Endocrinol. 2019;10:471. doi:10.3389/fendo.2019.00471
   PubMed Web of Science ®Google Scholar
• Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018;73(4):560–569. doi:10.1016/j.eururo.2017.12.01829325693
   PubMed Web of Science ®Google Scholar
• Zhou QH, Deng CZ, Li ZS, et al. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Cell Death Dis. 2018;9(6):684. doi:10.1038/s41419-018-0736-129880898
   PubMedGoogle Scholar
• Hu X, Chen M, Li Y, Wang Y, Wen S, Jun F. Overexpression of ID1 promotes tumor progression in penile squamous cell carcinoma. Oncol Rep. 2019;41(2):1091–1100. doi:10.3892/or.2018.691230535485
   PubMed Web of Science ®Google Scholar
• Jun F, Hong J, Liu Q, et al. Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma. Oncotarget. 2017;8(9):14343–14358. doi:10.18632/oncotarget.1110227527869
   PubMedGoogle Scholar
• Hu X, Chen M, Liu W, Li Y, Fu J. Preoperative plasma IGFBP2 is associated with nodal metastasis in patients with penile squamous cell carcinoma. Urol Oncol. 2019;37(7):452–461. doi:10.1016/j.urolonc.2019.04.01331053522
   PubMed Web of Science ®Google Scholar
• Hu X, Chen M, Li Y, Wang Y, Wen S, Aberrant JF. CEACAM19 expression is associated with metastatic phenotype in penile cancer. Cancer Manag Res. 2019;11:715–725. doi:10.2147/CMAR.S19238530679925
   PubMed Web of Science ®Google Scholar
• Peng H, Li Z, Fu J, Zhou R. Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma. Cancer Manag Res. 2019;11:2653–2661. doi:10.2147/CMAR.S19209531114328
   PubMed Web of Science ®Google Scholar
• Kuasne H, Cólus IM, Busso AF, et al. Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers. Clin Epigenetics. 2015;7(1):46. doi:10.1186/s13148-015-0082-425908946
   PubMedGoogle Scholar
• Spaks A. Role of CXC group chemokines in lung cancer development and progression. J Thorac Dis. 2017;9(Suppl 3):S164–S171. doi:10.21037/jtd.2017.03.6128446981
   PubMedGoogle Scholar
• Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998;187(4):655–660. doi:10.1084/jem.187.4.6559463416
   PubMed Web of Science ®Google Scholar
• Stratton KL, Culkin DJ, Contemporary A. Review of HPV and Penile Cancer. Oncology. 2016;30(3):245–249.26984219
   PubMed Web of Science ®Google Scholar
• Meng X, Yu X, Dong Q, et al. Distribution of circulating follicular helper T cells and expression of interleukin-21 and chemokine C-X-C ligand 13 in gastric cancer. Oncol Lett. 2018;16(3):3917–3922. doi:10.3892/ol.2018.911230128008
   PubMed Web of Science ®Google Scholar
• Panse J, Friedrichs K, Marx A, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer. 2008;99(6):930–938. doi:10.1038/sj.bjc.660462118781150
   PubMed Web of Science ®Google Scholar
• Zheng Z, Cai Y, Chen H, et al. CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma. Front Oncol. 2019;8:682. doi:10.3389/fonc.2018.0068230723697
   PubMed Web of Science ®Google Scholar
• Li B, Su H, Cao J, Zhang L. CXCL13 rather than IL-31 is a potential indicator in patients with hepatocellular carcinoma. Cytokine. 2017;89:91–97. doi:10.1016/j.cyto.2016.08.01627663978
   PubMed Web of Science ®Google Scholar
• Ritchie AW, Foster PW, Fowler S. BAUS Section of Oncology. Penile cancer in the UK: clinical presentation and outcome in 1998/99. BJU Int. 2004;94(9):1248–1252. doi:10.1111/j.1464-410X.2004.05152.x15610099
   PubMedGoogle Scholar
• El-Haibi CP, Singh R, Gupta P, et al. Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. J Proteomics Bioinform. 2012;5(8):177–184. doi:10.4172/jpb.100023224009409
   PubMedGoogle Scholar
• Xu L, Liang Z, Li S, Ma J. Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer. Oncol Lett. 2018;15(6):9293–9298. doi:10.3892/ol.2018.851029844827
   PubMed Web of Science ®Google Scholar